| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| AFX-5931 | AFX-5931 | Phase 2 Clinical | Afecta Pharmaceuticals Inc | Eczema | Details |
| MW-151 | MW01-9-034WH; MW-151; MW01-2-151SRM | Phase 1 Clinical | University Of Kentucky | Drug-Related Side Effects and Adverse Reactions; Poisoning | Details |
| 64CU-DOTA-ECL1i | Phase 1 Clinical | Washington University School Of Medicine | Arteriosclerosis; Carotid Artery Diseases; Heart Diseases | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Propagermanium | SK-818; SK-818C | Approved | Sanwa Kagaku Kenkyusho Co Ltd | Serocion | Japan | Hepatitis B | Sanwa Kagaku Kenkyusho Co Ltd | 1994-01-01 | Hepatitis B | Details |